Upper urinary tract urothelial carcinoma patients show better overall response rate than bladder cancer patients during enfortumab vedotin treatment following pembrolizumab.

ABSTRACT:

Background

The treatment strategy for urothelial carcinoma has advanced with the development of enfortumab vedotin (EV); however, a comparative analysis of its therapeutic efficacy between upper urinary tract urothelial carcinoma (UTUC) and bladder cancer (BCa) has yet to be established. We aimed to compare the effects of EV after pembrolizumab treatment between the patients with UTUC and BCa.

Methods

We included the patients with advanced UC patients who received EV after pembrolizumab in this retrospective study. We investigated the impact of various clinical variables including age, primary site of disease (UTUC vs. BCa), Liver metastasis, lung metastasis, prior number of regimens before EV treatment, and ECOG PS, which influenced on prognosis and efficacy of EV tr

SUBMITTER: Hashimoto M 

PROVIDER: S-EPMC12433179 | biostudies-literature | 2025 Aug

REPOSITORIES: biostudies-literature